etherna

etherna was founded in January 2013 as a spin-off company from the "Vrije Universiteit Brussel" (VUB), following the development of the TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy.

etherna is developing world-class mRNA immunotherapies for the treatment of cancer and infectious diseases. etherna uses messenger RNA to unleash and enhance a patient's immune response against a tumour or infectious agents. Research shows that this approach results in long-term clinical remission in cancer patients and protective immunity against infections.